Ametop - Friend and Foe A Prospective Study of the Incidence of Adverse Reactions With Ametop
Ametop - Friend or Foe A Prospective Observational Study of the Incidence of Adverse Reactions With Ametop
1 other identifier
observational
192
0 countries
N/A
Brief Summary
Ametop was introduced into the formulary as it was deemed more efficacious for intravenous cannulation compared to EMLA. However, the incidences of adverse reactions seemed to be higher compared to other studies. This lead to a prospective observational study to look at the incidence and severity of skin reactions following routine clinical application of Ametop.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Aug 2014
Shorter than P25 for all trials
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
August 1, 2014
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 1, 2015
CompletedStudy Completion
Last participant's last visit for all outcomes
May 1, 2015
CompletedFirst Submitted
Initial submission to the registry
April 17, 2016
CompletedFirst Posted
Study publicly available on registry
April 25, 2016
CompletedApril 25, 2016
April 1, 2016
9 months
April 17, 2016
April 22, 2016
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Incidence of skin reactions with Ametop
looking at the incidence of skin reactions with Ametop - normal, simple erythema, raised erythema, itch, pallor
October 2014 to May 2015
Secondary Outcomes (1)
Risk factors associated with incidence of skin reactions
October 2014 to May 2015
Interventions
Eligibility Criteria
Paediatric patients presenting for surgery in KK Women's and Children's Hospital
You may qualify if:
- All paediatric patients presenting for surgery from August 2014 to May 2015 who have had Ametop applied prior to intravenous cannulation.
You may not qualify if:
- Any patient who did not have Ametop applied or have an intravenous cannula in situ.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Related Publications (2)
Browne J, Awad I, Plant R, McAdoo J, Shorten G. Topical amethocaine (Ametop) is superior to EMLA for intravenous cannulation. Eutectic mixture of local anesthetics. Can J Anaesth. 1999 Nov;46(11):1014-8. doi: 10.1007/BF03013194.
PMID: 10566919BACKGROUNDArrowsmith J, Campbell C. A comparison of local anaesthetics for venepuncture. Arch Dis Child. 2000 Apr;82(4):309-10. doi: 10.1136/adc.82.4.309.
PMID: 10735838BACKGROUND
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Angela YJ Tan, MMed
KK Women's and Children's Hospital
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Sponsor Type
- OTHER GOV
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Senior Resident
Study Record Dates
First Submitted
April 17, 2016
First Posted
April 25, 2016
Study Start
August 1, 2014
Primary Completion
May 1, 2015
Study Completion
May 1, 2015
Last Updated
April 25, 2016
Record last verified: 2016-04
Data Sharing
- IPD Sharing
- Will not share
Data will be protected and not shared.